Development of personalized medicine: prospects and discussions
Personalized medicine is one of the most promising areas of current pharmacology. With more information about the genome, microbiome, way of life and other individual characteristics of the patient, it becomes possible to create medications that meet the needs of a particular person. This approach significantly increases the effectiveness of treatment and minimizes the risk of side effects. However, the development of personalized faces is accompanied by low click-through rates, which must be ensured.
What are personalized medicines?
Personalized medicinal products are drugs that are divided according to the individual characteristics of the patient. The basis of this approach is the analysis of genetic information, which allows us to transfer the body’s response to a different drug.
Applications of personalized therapies:
Gene therapy is aimed at correcting genetic defects.
Immunotherapy in oncology, for example, CAR-T cells, which are modified for a specific patient.
Treatments based on biomarkers, for example, drugs for breast cancer treatment (Herceptin).
Prospects for personalized medicine
1. Effectiveness of treatment
Personalized treatments allow you to achieve the maximum therapeutic effect. Instead of the standard “one drug for all” approach, doctors can choose treatments that work best for a particular patient.
2. Change in side effects
Through the analysis of genetic mutations, it is possible to identify certain drugs that may cause negative reactions.
3. Saving resources
Regardless of the high risk of complications, personalized medicine makes it possible to eliminate ineffective treatments and replace costs to reduce side effects.
4. Expanding the capabilities of treating foldable illnesses
Therapies that are based on unique patient characteristics offer new opportunities for treating rare and chronic diseases such as cystic fibrosis, cancer or autoimmune diseases.
Personalized medicine wikis
1. Foldability of the design
The development of personalized faces requires significant time, resources and follow-up. It is necessary to take into account a wide range of individual factors, such as genetics, microbiome, environment and way of life.
2. High Variety
Personalized therapies are often significantly more expensive than standard medications. For example, the Zolgensma gene therapy for spinal atrophy costs $2 million per dose.
3. Accessibility
Due to high costs, such services are often unavailable to most patients, especially in low- and middle-income countries.
4. Regulatory barriers
The praise of personalized faces requires more than a complicated and time-consuming process of clinical research. Regulatory authorities are responsible for adapting their provisions to the new type of drugs.
5. Ethical food
The collection of genetic data from patients raises concerns about confidentiality, data security, and ethics.
Successful cases of personalized medicine
Herceptin (trastuzumab): a drug for the treatment of breast cancer, which affects only patients with the presence of a human biomarker (HER2).
Kymriah (Novartis): CAR-T therapy for the treatment of acute lymphoblastic leukemia. This is personalized immunotherapy, which is based on the modification of the patient’s immune cells.
Kymriah (Novartis): CAR-T therapy for the treatment of acute lymphoblastic leukemia. This is personalized immunotherapy, which is based on the modification of the patient’s immune cells.
The Future of Personalized Medicine
Personalized faces will become the basis of future medicine due to the rapid development of such technologies as:
Genomics: reduced availability of genome sequencing to make DNA analysis available.
Piece intelligence: helps analyze large amounts of medical data and find individual solutions for patients.
CRISPR: gene editing technology that could become the basis for new gene therapies.
Telemedicine: helps integrate personalized approaches into routine medical practice.
The development of personalized medicines is a great step forward for pharmacology, which makes it possible to improve the capacity of medicine, change risks and ensure more rational use of resources. However, this will require significant investment, improved ethical and regulatory nutrition, as well as the development of accessible approaches for patients around the world.
The technology of processing organic high-molecular waste and materials (plastics, solid alternative fuel TAT, sewage sludge) by thermal depolymerization is not new from the point of view of the physicochemical process – equipment for thermal processing of raw materials was used as early as 1938 in Germany and England.
Sources of solid waste generation are organizations and enterprises, the population of city districts, and infrastructure facilities. The population accounts for the maximum amount of solid waste generated.
In our removal method, contact with the therapeutic agent composition is prolonged, and the composition acts as an activator, provoking the body’s immune system response to activate phagocytosis.